title: CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
abstract: Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies.
authors.affiliation: Department of Medicine, Center for Cell Engineering, and.
authors.forename: Jae H
authors.initials: JH
authors.lastname: Park
authors.affiliation: Department of Medicine.
authors.forename: Mark B
authors.identifier: 0000-0001-5248-9117
authors.initials: MB
authors.lastname: Geyer
authors.affiliation: Department of Medicine, Center for Cell Engineering, and Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Renier J
authors.initials: RJ
authors.lastname: Brentjens
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D018941:Antigens, CD19; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D019337:Hematologic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D013601:T-Lymphocytes / Q000637:transplantation*
chemical_list: D018941:Antigens, CD19; C000604811:CD19 molecule, human; D011948:Receptors, Antigen, T-Cell